ErVimmune
ErVimmune develops breakthrough immunotherapies based on the identification of a new class of tumor antigens, Human endogenous retrovirus (HERVs) shared across tumors and patients.
Lobbying Activity
Meeting with Vilija Sysaite (Cabinet of Executive Vice-President Stéphane Séjourné)
2 Apr 2025 · Biotech